Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD123 CAR-NK in Relapsed/Refractory AML or BPDCN
NCT06690827Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JD023 in acute myeloid leukemia (AML) and Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days, Objective Response Rate at 3 months and 4 more. Started Dec 2024; status: recruiting.
02
Drugs
JD023
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT06690827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690827.